en.Wedoany.com Reported - Eli Lilly and Company (Lilly) has announced the first clinical data for its investigational drug AJ1-11095, showing that this oral type II selective JAK2 inhibitor produced a high response rate in patients with previously treated myelofibrosis: 70% of patients achieved a best response of spleen volume reduction of 35% or greater (SVR35), and at week 12, 70% of patients experienced a 50% or greater improvement in symptom burden (TSS50). These data will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting, abstract number S218.
AJ1-11095 is a first-in-class drug designed to bind to the inactive conformation of JAK2. Lilly acquired the program following its acquisition of Ajax Therapeutics. The study is the Phase 1 AJX-101 trial, which enrolled 23 patients with primary or secondary myelofibrosis in the dose-escalation phase, who had received a median of 2 prior therapies and had all previously used type I JAK2 inhibitors. The study evaluated five once-daily dose levels: 25, 50, 75, 100, and 125 mg.
As of the data cutoff date of May 28, 2026, 21 of 23 patients showed a decrease in variant allele frequency (VAF) of driver mutations; as of May 12, 2026, among 17 patients at week 24, 59% had a VAF decrease of 20% or greater for JAK2, MPL, and CALR mutations, and 35% had a decrease of 50% or greater. In terms of safety, the overall profile was generally manageable, with no dose-limiting toxicities observed, and 78% of patients in the dose-escalation phase remained on study treatment. Common treatment-emergent adverse events included anemia, dysgeusia, decreased platelet count, and elevated alanine aminotransferase. AJ1-11095 is currently being evaluated in an expansion cohort in patients with second-line myelofibrosis, and studies are planned in high-risk polycythemia vera and treatment-naïve myelofibrosis (NCT06343805).
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
